A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors (NCT04587479) | Clinical Trial Compass
CompletedPhase 1
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
United States41 participantsStarted 2020-11-23
Plain-language summary
This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subject must be ≥18 years-of-age at the time of signature of the informed consent form (ICF).
✓. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
✓. Subjects with histologically or cytologically confirmed advanced solid tumors which have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or have a tumor for which no standard therapy(ies) exists.
✓. Subjects with life expectancy ≥3 months.
✓. Patients must have at least one measurable lesion as defined by RECIST v1.1.
✓. Patients who have sufficient baseline organ function.
Exclusion criteria
✕. History (≤3 years) of cancer that is histologically distinct from the cancer under study.
✕. Known serious allergy to investigational drug or excipients
✕. Active brain or spinal metastases
✕. History of pericarditis or Grade ≥2 pericardial effusion
✕. History of interstitial lung disease.
✕. History of Grade ≥2 active infections within 2 weeks
✕. Known human immunodeficiency virus (HIV) infection
What they're measuring
1
Number of participants with dose limiting toxicities